JD

Jijabai Dadaji Pawar

Active Director Director DIN 09840674
DIN 09840674 First appointment Dec 2022 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Jijabai Dadaji Pawar

Data last updated:

Jijabai Dadaji Pawar is a Director at Pramay Pharmaceuticals Private Limited (since 2022). The company operates in Chemicals.

DIN 09840674
Primary Designation Director
Industry Chemicals
First Appointment 28 Dec 2022
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director28 Dec 20222022Active

Board colleagues of Jijabai Dadaji Pawar

Directorship timeline

Open interactive timeline →
Pramay Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Jijabai Dadaji Pawar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jijabai Dadaji Pawar

Jijabai Dadaji Pawar currently holds 1 directorship: Pramay Pharmaceuticals Private Limited (Director, since 28 Dec 2022).

Jijabai Dadaji Pawar was first appointed on 28 Dec 2022 as Director at Pramay Pharmaceuticals Private Limited.

The current boards of Jijabai Dadaji Pawar's companies include Manisha Neelkanth Bankar (Pramay Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available